Article

Systems pharmacology and genome medicine: A future perspective

Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA.
Genome Medicine (Impact Factor: 5.34). 02/2009; 1(1):11. DOI: 10.1186/gm11
Source: PubMed

ABSTRACT

Genome medicine uses genomic information in the diagnosis of disease and in prescribing treatment. This transdisciplinary field brings together knowledge on the relationships between genetics, pathophysiology and pharmacology. Systems pharmacology aims to understand the actions and adverse effects of drugs by considering targets in the context of the biological networks in which they exist. Genome medicine forms the base on which systems pharmacology can develop. Experimental and computational approaches enable systems pharmacology to obtain holistic, mechanistic information on disease networks and drug responses, and to identify new drug targets and specific drug combinations. Network analyses of interactions involved in pathophysiology and drug response across various scales of organization, from molecular to organismal, will allow the integration of the systems-level understanding of drug action with genome medicine. The interface of the two fields will enable drug discovery for personalized medicine. Here we provide a perspective on the questions and approaches that drive the development of these new interrelated fields.

Full-text preview

Available from: PubMed Central
  • Source
    • "As well as our own findings in yeast (Lanthaler et al., 2011), the recent availability of a great many mutants in a near-haploid human cell line (Bürckstümmer et al., 2013) opens up many possibilities for determining which drugs use which transporters, as is nicely illustrated by Superti- Furga and colleagues (Winter et al., 2014). This will be an important contribution to the emerging recognition that to make real progress we need to move to a systems pharmacology (e.g., van der Greef and McBurney, 2005; Kell and Goodacre, 2014; Bai and Abernethy, 2013; Benson et al., 2014; Berger and Iyengar, 2009; Cucurull-Sanchez et al., 2012; Rostami-Hodjegan, 2012; van der Graaf and Benson, 2011; Vicini and van der Graaf, 2013; Waldman and Terzic, 2012; Wist et al., 2009; Zhao and Iyengar, 2012; Zhao et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Several recent developments are brought together: (i) the new availability of a consensus, curated human metabolic network reconstruction (Recon2), approximately a third of whose steps are represented by transporters, (ii) the recognition that most successful (marketed) drugs, as well as natural products, bear significant similarities to the metabolites in Recon2, (iii) the recognition that to get into and out of cells such drugs hitchhike on the transporters that are part of normal intermediary metabolism, and the consequent recognition that for intact biomembrane Phospholipid Bilayer diffusion Is Negligible (PBIN), and (iv) the consequent recognition that we need to exploit this and to use more phenotypic assays to understand how drugs affect cells and organisms. I show in particular that lipophilicity is a very poor predictor of drug permeability, and that we need to (and can) bring together our knowledge of both pharmacology and systems biology modelling into a new systems pharmacology.
    Full-text · Article · Oct 2015
  • Source
    • "Our current study predicted signaling pathway memberships for 5 currently used drug target proteins and suggested 14 additional proteins that can be used as novel drug target candidates, based on their predicted pathway annotations and other properties (Table 2). Our predictions may (i) reveal novel therapeutic intervention points (e.g., the use of signalogs as novel targets to block specific pathways); (ii) suggest novel applications of current drugs to diseases, where the newly predicted signaling pathway of their target is relevant, and (iii) help to identify possible side effects of currently used drugs [59], [64], [65]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Uncovering novel components of signal transduction pathways and their interactions within species is a central task in current biological research. Orthology alignment and functional genomics approaches allow the effective identification of signaling proteins by cross-species data integration. Recently, functional annotation of orthologs was transferred across organisms to predict novel roles for proteins. Despite the wide use of these methods, annotation of complete signaling pathways has not yet been transferred systematically between species.
    Full-text · Article · May 2011 · PLoS ONE
  • Source
    • "We may retranslate modularly induced functional changes in tumors into intentional knowledge by comparatively reconstructing novel communication-linked processes on a biochemical basis to (1) prove the formal-pragmatic communication theory by an intentional and computational idealization [28, 29], and to (2) advance reductionist knowledge for novel reductionist therapy approaches, which may be used in parallel or subsequentially. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nature is interwoven with communication and is represented and reproduced through communication acts. The central question is how may multimodal modularly acting and less toxic therapy approaches, defined as modular therapies, induce an objective response or even a continuous complete remission, although single stimulatory or inhibitingly acting drugs neither exert mono-activity in the respective metastatic tumor type nor are they directed to potentially 'tumor-specific' targets. Modularity in the present context is a formal pragmatic communicative systems concept, describing the degree to which systems objects (cells, pathways etc.) may be communicatively separated in a virtual continuum, and recombined and rededicated to alter validity and denotation of communication processes in the tumor. Intentional knowledge, discharging in reductionist therapies, disregards the risk-absorbing background knowledge of the tumor's living world including the holistic communication processes, which we rely on in every therapy. At first, this knowledge constitutes the validity of informative intercellular processes, which is the prerequisite for therapeutic success. All communication-relevant steps, such as intentions, understandings, and the appreciation of messages, may be modulated simultaneously, even with a high grade of specificity. Thus, modular therapy approaches including risk-absorbing and validity-modifying background knowledge may overcome reductionist idealizations. Modular therapies show modular events assembled by the tumor's living world as an additional evolution-constituting dimension. This way, modular knowledge may be acquired from the environment, either incidentally or constitutionally. The new communicatively defined modular coherency of environment, i.e. the tumor-associated microenvironment, and tumor cells open novel ways for the scientific community in 'translational medicine'.
    Full-text · Article · Aug 2009 · Cancer Microenvironment
Show more